Peringkat dalam Saham
#25934
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Kapitalisasi Pasar
$46.24M
Perubahan (1 hari)
-16.52%
Perubahan (1 tahun)
103.39%
Perdagangan Edesa Biotech, Inc. (EDSA)
Harga EDSA dengan kapitalisasi pasar B
Kapitalisasi pasar dari Edesa Biotech, Inc.(EDSA)
Kapitalisasi Pasar: $46.24M
Per August 2026, Edesa Biotech, Inc. memiliki kapitalisasi pasar sebesar $46.24M. Ini menjadikan Edesa Biotech, Inc. sebagai perusahaan 25934th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Edesa Biotech, Inc. dari 2010 hingga 2026
EDSA dibandingkan dengan 5 teratas stocks paling populer
| Harga EDSA |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.257T
|
+11,368,556.10%
|
|
|
|
|
$4.599T
|
+9,945,110.35%
|
|
|
|
|
$4.106T
|
+8,879,897.31%
|
|
|
|
|
$3.577T
|
+7,736,196.86%
|
|
|
|
|
$2.807T
|
+6,071,079.53%
|
